2015

Defining new therapeutics using a more immunocompetent mouse model of antibody-enhanced dengue virus infection

Amelia K. Pinto
*Washington University School of Medicine in St. Louis*

James D. Brien
*Washington University School of Medicine in St. Louis*

Chia-Ying Kao Lam
*MacroGenics, Inc.*

Syd Johnson
*MacroGenics, Inc.*

Cindy Chiang
*Pasteur Institute of Rome*

See next page for additional authors

Follow this and additional works at: [http://digitalcommons.wustl.edu/open_access_pubs](http://digitalcommons.wustl.edu/open_access_pubs)

Recommended Citation
[http://digitalcommons.wustl.edu/open_access_pubs/4213](http://digitalcommons.wustl.edu/open_access_pubs/4213)
Defining New Therapeutics Using a More Immunocompetent Mouse Model of Antibody-Enhanced Dengue Virus Infection


ABSTRACT  With over 3.5 billion people at risk and approximately 390 million human infections per year, dengue virus (DENV) disease strains health care resources worldwide. Previously, we and others established models for DENV pathogenesis in mice that completely lack subunits of the receptors (Ifnar and Ifngr) for type I and type II interferon (IFN) signaling; however, the utility of these models is limited by the pleotropic effect of these cytokines on innate and adaptive immune system development and function. Here, we demonstrate that the specific deletion of Ifnar expression on subsets of murine myeloid cells (LysM Cre⁺ Ifnarⅅox/ⅅox [denoted as Ifnarⅅf/f herein]) resulted in enhanced DENV replication in vivo. The administration of subneutralizing amounts of cross-reactive anti-DENV monoclonal antibodies to LysM Cre⁺ Ifnarⅅf/f mice prior to infection with DENV serotype 2 or 3 resulted in antibody-dependent enhancement (ADE) of infection with many of the characteristics associated with severe DENV disease in humans, including plasma leakage, hypercytokinemia, liver injury, hemoconcentration, and thrombocytopenia. Notably, the pathogenesis of severe DENV-2 or DENV-3 infection in LysM Cre⁺ Ifnarⅅf/f mice was blocked by pre- or postexposure administration of a bispecific dual-affinity retargeting molecule (DART) or an optimized RIG-I receptor agonist that stimulates innate immune responses. Our findings establish a more immunocompetent animal model of ADE of infection with multiple DENV serotypes in which disease is inhibited by treatment with broad-spectrum antibody derivatives or innate immune stimulatory agents.

IMPORTANCE  Although dengue virus (DENV) infects hundreds of millions of people annually and results in morbidity and mortality on a global scale, there are no approved antiviral treatments or vaccines. Part of the difficulty in evaluating therapeutic candidates is the lack of small animal models that are permissive to DENV and recapitulate the clinical features of severe human disease. Using animals lacking the type I interferon receptor only on myeloid cell subsets, we developed a more immunocompetent mouse model of severe DENV infection with characteristics of the human disease, including vascular leakage, hemoconcentration, thrombocytopenia, and liver injury. Using this model, we demonstrate that pathogenesis by two different DENV serotypes is inhibited by therapeutic administration of a genetically modified antibody or a RIG-I receptor agonist that stimulates innate immunity.
DIII), with E-DII and E-DIII containing the fusion peptide and putative viral receptor binding site(s), respectively (reviewed in references 4 and 5). Among the structural proteins, prM and E are the primary antigenic targets of the humoral immune response (6–9). The most potently neutralizing antibodies target sites on the lateral ridge and A strand of E-DIII (10–16), quaternary epitopes on adjacent E proteins near the E-DII hinge region (17–20), amino acids near the bc loop of E-DII (21), and a conserved epitope at the E dimer interface (22).

One hypothesis as to why certain individuals are more vulnerable to severe DENV infection is that preexisting, poorly neutralizing antibodies acquired passively (infants) or after primary infection (children and adults) facilitate virus entry into Fcγ receptor (FcγR)-bearing target cells, thereby increasing viral replication, cytokine levels, inflammation, and ultimately, disease severity (reviewed in reference 23). Experimental evidence in mice supports this idea. Initial studies showed that passive transfer of subneutralizing concentrations of monoclonal antibody (MAb) or polyclonal antibody (PAb) enhanced infection and disease caused by DENV-2 in 129/Sv mice deficient in both alpha/beta interferon (IFN-α/β) receptor (Ifnar) and IFN-γ receptor (Ifngr) (known as AG129) (24–26). Subsequent reports extended these findings to other DENV serotypes in AG129 mice (DENV-1 [19], DENV-3 [27], and DENV-4 [13, 28, 29]) or Ifnar-/- mice in either the 129/Sv or C57BL/6 background develop a severe DENV-like disease when infected with very high DENV-2 doses or in the presence of enhancing anti-DENV antibodies (25, 30–33).

The utility of these highly immunocompromised mice to provide a mechanistic understanding of DENV pathogenesis and disease remains controversial. The use of laboratory or mouse-adapted DENV-2 strains has been required to induce mortality or neuroinvasive disease (34), and the latter is not commonly observed in DENV-infected humans. Studies with DENV-2 indicate that mice with deficiencies in innate immunity are needed to study DENV pathogenesis because the viral NS5 and NS5 proteins induce degradation of human but not mouse STING and STAT2, respectively (35–38); STING and STAT2 are key components of the IFN induction and signaling pathway. Thus, DENV generally does not replicate to high titers or cause clinical signs of disease in wild-type (WT) mice, in part because DENV nonstructural proteins fail to antagonize host innate immune responses efficiently. We recently demonstrated that WN V infection of the more immunocompetent LysM Cre+ Ifnar\textsuperscript{floox/floox} (denoted as Ifnar\textsuperscript{floox} herein) or C11c Cre+ Ifnar\textsuperscript{floox} mice, which lack Ifnar expression only on subsets of myeloid cells, resulted in a lethal, systemic-like disease that shared features of DENV disease in humans (39). Another group recently used the LysM Cre+ Ifnar\textsuperscript{floox} and C11c Cre+ Ifnar\textsuperscript{floox} mice to generate a model of DENV-2 infection and study adaptive immunity after immunization with a candidate vaccine (40). Here, we administered enhancing amounts of anti-E and anti-prM MAbs to LysM Cre+ Ifnar\textsuperscript{floox} mice prior to infection with either DENV-2 or DENV-3 and generated an antibody-dependent enhancement (ADE) of infection model of disease that shared many characteristics of severe dengue in humans. We used this model to establish the therapeutic efficacy of an antibody-based bispecific dual-affinity retargeting molecule (DART) that targets epitopes on the A strand of E-DIII and the fusion loop in E-DII and a novel sequence-optimized RIG-1 receptor agonist that stimulates antiviral innate immunity. These studies provide the first demonstration of severe ADE-mediated DENV infection in LysM Cre+ Ifnar\textsuperscript{floox} mice and illustrate the utility of this model to evaluate antibody- and innate immune-based antiviral therapies to limit DENV pathogenesis.

RESULTS

Dengue virus infection in LysM Cre+ Ifnar\textsuperscript{floox} mice. Prior analysis established that myeloid cells are targets for human DENV infection in vivo (41). The relevance of Ifnar-/- mice in studying DENV pathogenesis has been questioned because of the central role of IFN signaling in priming innate and adaptive immune responses (42–44). In an attempt to study DENV pathogenesis in a more immunocompetent animal, we used LysM Cre+ Ifnar\textsuperscript{floox} mice that conditionally delete Ifnar only in subsets of myeloid cells. In splenocytes, flow cytometric analysis revealed substantially reduced Ifnar expression on the surface of CD11b\textsuperscript{hi} CD11c\textsuperscript{lo} macrophages from LysM Cre+ Ifnar\textsuperscript{floox} mice compared to the results for WT mice. In contrast, the levels of Ifnar expression on B220+ B cells, CD3+ T cells, CD11b\textsuperscript{hi} CD11c\textsuperscript{lo} monocytes, and CD11b\textsuperscript{lo} CD11c\textsuperscript{hi} dendritic cells from LysM Cre+ Ifnar\textsuperscript{floox} mice were comparable to the levels seen in WT mice (Fig. 1A).

Initially, we compared morbidity in DENV-infected WT, LysM Cre+ Ifnar\textsuperscript{floox} and Ifnar-/- mice. Four-week-old mice lacking Ifnar expression on all cells or only on myeloid cell subsets rapidly developed disease within days of DENV-2 (strain D2S20, 1 x 10\textsuperscript{7} FFU) infection, as reflected by the development of weight loss (Fig. 1B and C) ruffled fur, and hunched appearance (data not shown). In comparison, and as expected, WT mice infected with DENV-2 or DENV-3 did not develop signs of disease.

To define the basis for the DENV-induced disease in LysM Cre+ Ifnar\textsuperscript{floox} mice, we assessed viral burdens. WT, LysM Cre+ Ifnar\textsuperscript{floox}, and Ifnar-/- mice were inoculated intravenously with 1 x 10\textsuperscript{6} focus-forming units [FFU] or DENV-3 (strain C0360/94, 1 x 10\textsuperscript{7} FFU) infection, as reflected by the development of weight loss (Fig. 1B and C) ruffled fur, and hunched appearance (data not shown). In comparison, and as expected, WT mice infected with DENV-2 or DENV-3 did not develop signs of disease.

Antibody-enhanced DENV disease in LysM Cre+ Ifnar\textsuperscript{floox} mice. Given that LysM Cre+ Ifnar\textsuperscript{floox} mice sustained infection and disease after DENV inoculation, we evaluated whether more severe disease would be observed if enhancing and cross-reactive anti-prM (2H2) and anti-E (4G2) MAbs were administered. In WT mice, more severe disease was observed in LysM Cre+ Ifnar\textsuperscript{floox} mice that were treated with enhancing MAbs than in those treated with an isotype control anti-Chikungunya virus MAb (CHK-152) (45) prior to infection with 1 x 10\textsuperscript{7} FFU of DENV-2 (strain D2S20, 1 x 10\textsuperscript{6} FFU) dose of DENV-2, even in the presence of enhancing MAbs (data not shown). With a higher dose of DENV-2 (1 x 10\textsuperscript{7} FFU), we did observe increased mortality under ADE conditions (55 versus 8 percent mortality; P < 0.006) (Fig. 2B). As DENV infection in humans is predominantly a disease that does not cause lethality, we performed subsequent experiments using the lower 1 x 10\textsuperscript{6} FFU dose of DENV-2.

To define the relevance of the LysM Cre+ Ifnar\textsuperscript{floox} mouse model of DENV-2 infection, we assessed the impact of ADE on labora-
Hemoconcentration (shown by elevated hematocrit [HCT]), which reflects changes in vascular permeability, was observed in DENV-infected LysM Cre<sup>+</sup> Ifnar<sup>−/−</sup> mice, and this phenotype was exacerbated in the presence of enhancing antibodies (HCT was 42 for no virus, 46 for DENV-2 alone, and 51 for DENV-2 plus anti-prM and anti-E MAbs) (Fig. 2C). Thrombocytopenia (low platelet [PLT] counts) was also detected.
DENV-infected LysM Cre⁺ Ifnar⁻/⁻ mice, although ADE did not alter its magnitude (PLT count was 300 ± 85 for no virus, 108 ± 59 for DENV-2 alone, and 155 ± 67 for DENV-2 plus anti-prM and anti-E MABS) (Fig. 2D). An elevated blood urea nitrogen (BUN) level, which reflects renal damage, was measured only in DENV-infected LysM Cre⁺ Ifnar⁻/⁻ mice treated with enhancing antibodies (BUN was 15 ± 4 for no virus, 16 ± 4 for DENV-2 alone, and 68 ± 21 for DENV-2 plus anti-prM and anti-E MABS) (Fig. 2E). Liver injury, as manifested by elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels in serum, was also observed in DENV-infected LysM Cre⁺ Ifnar⁻/⁻ mice, with greater damage present under conditions of ADE (AST and ALT were 156 ± 49 and 82 ± 36, respectively, for no virus, 300 ± 208 and 125 ± 53 for DENV-2 alone, and 503 ± 223 and 258 ± 149 for DENV-2 plus anti-prM and anti-E MABS) (Fig. 2F and G). Overall, enhancing antibodies in the context of DENV infection of LysM Cre⁺ Ifnar⁻/⁻ mice worsened many of the laboratory parameters that are seen during cases of severe DENV in humans (46). In comparison, in Ifnar⁻/⁻ mice, the administration of enhancing antibodies resulted in an increased hematocrit (44 ± 3 for DENV-2 alone and 53 ± 9 for DENV-2 plus anti-prM and anti-E MABS) but did not alter AST or ALT levels or platelet counts beyond that seen with virus alone (data not shown).

To determine the basis for the exacerbated clinical disease in LysM Cre⁺ Ifnar⁻/⁻ mice, we assessed the effects of enhancing antibodies on the DENV-2 viral burden. At day 4 after infection, we observed higher levels of DENV RNA in the sera of infected LysM Cre⁺ Ifnar⁻/⁻ than in the sera of WT mice, with further increases when animals were pretreated with enhancing MAbs (Fig. 3A). Analogous results were observed in other tissues after DENV infection and antibody treatment, including the kidney, spleen, and liver (Fig. 3B to D).

We evaluated cytokine levels in serum and vascular leakage in tissues, which are two features of severe DENV infection in humans (23, 47). Elevated levels of interleukin 1β (IL-1β) and IL-12 were observed in LysM Cre⁺ Ifnar⁻/⁻ mice compared to the levels in...
WT mice after DENV-2 infection (Fig. 3E and F). Moreover, in the setting of ADE, the levels of several other proinflammatory cytokines were substantially higher in LysM Cre<sup>−/Ifnar<sup>f/f mice than they were in the setting of DENV infection alone (Fig. 3G and H; Table 1). Since previous studies in DENV-infected AG129 mice demonstrated increased vascular permeability in the liver (24, 25, 27), we performed similar studies in LysM Cre<sup>−/Ifnar<sup>f/f mice (Fig. 3I to L).

Leakage of Evans blue dye into the kidney and liver was observed at day 4 after DENV infection in the context of ADE in LysM Cre<sup>−/Ifnar<sup>f/f mice, which parallels the enhanced capillary permeability seen during severe DENV disease in humans (48). However, the increased dye extravasation was tissue restricted and was not observed in the spleen or small intestine of these mice.

To corroborate these findings, we performed analogous experiments with enhancing MAbs in DENV-3-infected LysM Cre<sup>−/Ifnar<sup>f/f mice using a non-mouse-adapted DENV-3 human isolate (strain C0360/94) (27). Although lethal infection was not observed in this model at a dose of 1 × 10<sup>7</sup> FFU, some mortality (~33%) was seen at a dose of 3 × 10<sup>7</sup> FFU in A129 mice (data not shown). More severe DENV-3-induced disease occurred in LysM Cre<sup>−/Ifnar<sup>f/f but not WT mice when enhancing amounts of anti-E MAb were present, as determined by greater weight loss (Fig. 4A; also data not shown). The addition of the anti-prM MAb to the anti-E MAb did not worsen clinical disease further after DENV-3 infection of LysM Cre<sup>−/Ifnar<sup>f/f mice (data not shown), and thus, it was not included in subsequent experiments.

Virologic and clinical laboratory studies were performed after DENV-3 infection in WT and LysM Cre<sup>−/Ifnar<sup>f/f mice. Higher viral burdens at day 4 after DENV-3 infection were observed in LysM Cre<sup>−/Ifnar<sup>f/f mice only when enhancing anti-E MAb was administered (Fig. 4B to E; also data not shown). Hemocencentration, lower platelet levels, enhanced liver enzymes (elevated AST and ALT), and renal injury (elevated BUN) were also observed in LysM Cre<sup>−/Ifnar<sup>f/f mice after DENV-3 infection in the presence of enhancing antibodies (Fig. 4F to J). Thus, the LysM

WT mice after DENV-2 infection (Fig. 3E and F). Moreover, in the setting of ADE, the levels of several other proinflammatory cytokines were substantially higher in LysM Cre<sup>−/Ifnar<sup>f/f mice than they were in the setting of DENV infection alone (Fig. 3G and H; Table 1). Since previous studies in DENV-infected AG129 mice demonstrated increased vascular permeability in the liver (24, 25, 27), as measured by extravasation of Evans blue dye, we performed similar studies in LysM Cre<sup>−/Ifnar<sup>f/f mice (Fig. 3I to L). Leakage of Evans blue dye into the kidney and liver was observed at day 4 after DENV infection in the context of ADE in LysM Cre<sup>−/Ifnar<sup>f/f mice, which parallels the enhanced capillary permeability seen during severe DENV disease in humans (48). However, the increased dye extravasation was tissue restricted and was not observed in the spleen or small intestine of these mice.

To corroborate these findings, we performed analogous experiments with enhancing MAbs in DENV-3-infected LysM Cre<sup>−/Ifnar<sup>f/f mice using a non-mouse-adapted DENV-3 human isolate (strain C0360/94) (27). Although lethal infection was not observed in this model at a dose of 1 × 10<sup>7</sup> FFU, some mortality (~33%) was seen at a dose of 3 × 10<sup>7</sup> FFU in A129 mice (data not shown). More severe DENV-3-induced disease occurred in LysM Cre<sup>−/Ifnar<sup>f/f but not WT mice when enhancing amounts of anti-E MAb were present, as determined by greater weight loss (Fig. 4A; also data not shown). The addition of the anti-prM MAb to the anti-E MAb did not worsen clinical disease further after DENV-3 infection of LysM Cre<sup>−/Ifnar<sup>f/f mice (data not shown), and thus, it was not included in subsequent experiments.

Virologic and clinical laboratory studies were performed after DENV-3 infection in WT and LysM Cre<sup>−/Ifnar<sup>f/f mice. Higher viral burdens at day 4 after DENV-3 infection were observed in LysM Cre<sup>−/Ifnar<sup>f/f mice only when enhancing anti-E MAb was administered (Fig. 4B to E; also data not shown). Hemocencentration, lower platelet levels, enhanced liver enzymes (elevated AST and ALT), and renal injury (elevated BUN) were also observed in LysM Cre<sup>−/Ifnar<sup>f/f mice after DENV-3 infection in the presence of enhancing antibodies (Fig. 4F to J). Thus, the LysM
Cre+ Ifnar−/− mouse model shows enhanced disease in the setting of ADE of two different DENV serotypes. A bispecific tetravalent Fc-DART protects against DENV infection in LysM Cre+ Ifnar−/− mice. Previously, we generated an antibody-variable-region-based bispecific Ig-DART against DENV that targeted two distinct epitopes (49). That DART used WNV-E60, a cross-reactive neutralizing MAb that binds the A-strand epitope on DIII. Our subsequent studies revealed that a second DIII fusion loop antibody, WNV-E119 (50), had superior inhibitory activity against other DENV serotypes (13; also data not shown). Accordingly, we generated a new bispecific tetravalent DART that contained the VH and VL regions of humanized WNV-E119 (hE119) and humanized 4E11 (h4E11) (Fig. 5A) (51, 52). This Fc-DART was engineered with the human IgG Fc constant regions (CH1, CH2, and CH3) containing a point mutation (N297Q) that prevents FcγR engagement and ADE (26). A nonbinding, bivalent DENV type-specific IgG was developed as a negative control (Fig. 5A).

The initial studies confirmed the in vitro binding activity of N297Q h4E11 plus hWNV-E119A against recombinant E protein from prototype strains of all four DENV serotypes (data not shown). We next investigated the neutralization potential of the Fc-DART against the viruses we used for the in vivo studies and compared it to that of the parental h4E11 and hWNV-E119 MAbs. The h4E11 MAb efficiently neutralized DENV-2 (50% effective concentration [EC50] of 20 ng/ml) and DENV-3 (EC50 of 29 ng/ml) (Fig. 5B and C). In comparison, the hWNV-E119 MAb neutralized DENV-2 (EC50 of 120 ng/ml) but not DENV-3 strain C0360/94. The h4E11–hWNV-E119A N297Q bispecific Fc-DART showed a neutralization profile that was consistent with the inhibitory activity of h4E11.

To assess the utility of the LysM Cre+ Ifnar−/− mouse model of ADE and DENV pathogenesis, we performed protection studies using the bispecific N297Q Fc-DART. Initially, prophylaxis studies were performed against DENV-2. One 25-μg dose of the bispecific h4E11–hWNV-E119 N297Q Fc-DART administered one day prior to DENV-2 inoculation and enhancing treatment with anti-E plus anti-prM MAb completely protected LysM Cre+ Ifnar−/− mice against weight loss, viremia, thrombocytopenia, hemocencentration, and liver injury (data not shown). Subsequently, LysM Cre+ Ifnar−/− mice were administered a single 25-μg dose of the bispecific N297Q Fc-DART 48 h after infection with DENV-2 or DENV-3 (Fig. 5D). The hE11–hWNV-E119 Fc-DART was active therapeutically, as judged by increased weight gain, reduced viral burden, and improved laboratory test values at 4 days after infection in the setting of ADE for either DENV-2 (Fig. 5E to J) and DENV-3 (Fig. 5K to P).

A RIG-I receptor agonist protects against severe DENV infection in LysM Cre+ Ifnar−/− but not Ifnar−/− mice. One of the limitations of using Ifnar−/− or AG129 mice is that the complete absence of IFNAR signaling does not permit the evaluation of anti-DENV therapies that act by modulating the host innate immune response. Recently, members of our group developed a 99-nucleotide, uridine-rich hairpin 5′-ppp RNA (termed M8) RIG-I agonist that can be delivered in vivo to stimulate protective antiviral responses against alphaviruses and orthomyxoviruses (53). We tested the utility of the LysM Cre+ Ifnar−/− model by administering M8 5′-ppp RNA in parallel to LysM Cre+ Ifnar−/− and Ifnar−/− mice prior to and after the addition of enhancing anti-prM and -E MAbs and DENV-2 (Fig. 6A). Protection, as judged by the absence of weight loss, was observed only in LysM Cre+ Ifnar−/− and not in Ifnar−/− mice (Fig. 6B). Associated with this clinical improvement, at day 4, we observed decreased viremia (Fig. 6C),

<table>
<thead>
<tr>
<th>Mouse treatment</th>
<th>WT mice, no MAb</th>
<th>LysM Cre+ Ifnar−/− mice, isotype MAb (P value vs WT)</th>
<th>LysM Cre+ Ifnar−/− mice, prM and E MAbs (P value vs WT; P value vs isotype MAb)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-1α</td>
<td>5 ± 1</td>
<td>16 ± 2 (&lt;0.0001)</td>
<td>20 ± 4 (&lt;0.0001; NS)</td>
</tr>
<tr>
<td>IL-1β</td>
<td>134 ± 23</td>
<td>262 ± 13 (&lt;0.0001)</td>
<td>609 ± 45 (&lt;0.0001; &lt;0.0001)</td>
</tr>
<tr>
<td>IL-2</td>
<td>24 ± 1</td>
<td>42 ± 5 (0.01)</td>
<td>48 ± 6 (0.01; NS)</td>
</tr>
<tr>
<td>IL-3</td>
<td>23 ± 1</td>
<td>62 ± 9 (0.01)</td>
<td>93 ± 3 (&lt;0.0001; 0.01)</td>
</tr>
<tr>
<td>IL-4</td>
<td>16 ± 2</td>
<td>47 ± 5 (&lt;0.0001)</td>
<td>50 ± 8 (0.001; NS)</td>
</tr>
<tr>
<td>IL-5</td>
<td>24 ± 4</td>
<td>89 ± 10 (&lt;0.0001)</td>
<td>100 ± 11 (&lt;0.0001; NS)</td>
</tr>
<tr>
<td>IL-6</td>
<td>35 ± 7</td>
<td>86 ± 17 (0.001)</td>
<td>88 ± 5 (&lt;0.0001; NS)</td>
</tr>
<tr>
<td>IL-10</td>
<td>52 ± 6</td>
<td>62 ± 6 (NS)</td>
<td>80 ± 10 (NS; NS)</td>
</tr>
<tr>
<td>IL-12(p40)</td>
<td>59 ± 6</td>
<td>79 ± 12 (NS)</td>
<td>215 ± 49 (&lt;0.0001; 0.0001)</td>
</tr>
<tr>
<td>IL-12(p70)</td>
<td>50 ± 6</td>
<td>71 ± 4 (0.01)</td>
<td>196 ± 22 (&lt;0.0001; &lt;0.0001)</td>
</tr>
<tr>
<td>IL-13</td>
<td>28 ± 3</td>
<td>44 ± 5 (0.04)</td>
<td>51 ± 7 (0.0026; NS)</td>
</tr>
<tr>
<td>IL-17</td>
<td>18 ± 1</td>
<td>40 ± 6 (0.02)</td>
<td>60 ± 4 (&lt;0.0001; 0.007)</td>
</tr>
<tr>
<td>Eotaxin</td>
<td>592 ± 35</td>
<td>595 ± 101 (NS)</td>
<td>1,092 ± 165 (NS; 0.008)</td>
</tr>
<tr>
<td>G-CSF</td>
<td>110 ± 10</td>
<td>322 ± 73 (0.0004)</td>
<td>3,081 ± 745 (&lt;0.0001; &lt;0.0001)</td>
</tr>
<tr>
<td>GM-CSF</td>
<td>64 ± 4</td>
<td>76 ± 15 (NS)</td>
<td>214 ± 7 (&lt;0.0001; &lt;0.0001)</td>
</tr>
<tr>
<td>IFN-γ</td>
<td>14 ± 1</td>
<td>17 ± 3 (NS)</td>
<td>36 ± 6 (&lt;0.0001; 0.002)</td>
</tr>
<tr>
<td>KC</td>
<td>48 ± 7</td>
<td>111 ± 11 (&lt;0.0001)</td>
<td>1,171 ± 307 (&lt;0.0001; &lt;0.0001)</td>
</tr>
<tr>
<td>MCP-1</td>
<td>219 ± 34</td>
<td>712 ± 92 (&lt;0.0001)</td>
<td>1,973 ± 349 (&lt;0.0001; &lt;0.0001)</td>
</tr>
<tr>
<td>MIP-1α</td>
<td>5 ± 0</td>
<td>8 ± 1 (NS)</td>
<td>25 ± 1 (&lt;0.0001; &lt;0.0001)</td>
</tr>
<tr>
<td>MIP-1β</td>
<td>41 ± 9</td>
<td>74 ± 6 (0.0014)</td>
<td>135 ± 7 (&lt;0.0001; &lt;0.0001)</td>
</tr>
<tr>
<td>RANTES</td>
<td>7 ± 1</td>
<td>20 ± 8 (&lt;0.0001)</td>
<td>323 ± 113 (&lt;0.0001; &lt;0.0001)</td>
</tr>
<tr>
<td>TNF-α</td>
<td>480 ± 81</td>
<td>609 ± 50 (NS)</td>
<td>1,815 ± 221 (&lt;0.0001; &lt;0.0001)</td>
</tr>
</tbody>
</table>

* Mice were pretreated with the indicated MAbs (none, isotype control anti-CHK-152, or enhancing anti-prM and anti-E MAbs) one day prior to infection with DENV-2. On day 4 after infection, sera were harvested and processed for cytokines and chemokines as described in Materials and Methods. Data from 9 to 12 mice per group in three or four independent experiments were pooled. Statistical significance was assessed using the Mann-Whitney test. NS, not significant.
FIG 4 Weight loss, viral burdens, hematology, and blood chemistry for DENV-3-infected WT and LysM Cre \(^{+}\) Ifnar\(^{-}\/-\) mice under ADE conditions. WT or LysM Cre \(^{+}\) Ifnar\(^{-}\/-\) mice received passively transferred isotype control MAb (10 \(\mu\)g of CHK-152) or enhancing MAb (10 \(\mu\)g of anti-E MAb [4G2]) and were infected a day later with \(10^7\) FFU of DENV-3 (strain C0360/94) via an intravenous route. (A) Weight change was monitored daily in four independent experiments with 4 to 5 mice per group per experiment. (B to E) Levels of viral RNA in serum (B), spleen (C), liver (D), and kidney (E) samples harvested 4 days after infection were determined using qRT-PCR. Data are shown as log10 DENV genome equivalents (GE) per 18S of tissue or per milliliter of serum from 9 to 12 mice per condition. The dotted line represents the limit of sensitivity of the assay. Asterisks indicate values that are statistically significant compared to the values for isotype control MAb-treated animals. (F to J) LysM Cre \(^{+}\) Ifnar\(^{-}\/-\) mice were either not infected (naive, no virus) or were administered isotype control (anti-CHK152) or enhancing anti-E MAb one day before DENV-3 infection. Whole blood was collected at day 4 after infection, and hematocrit (F) and platelet counts (G) were analyzed. Clinical chemistry analysis was performed on serum and included measurement of blood urea nitrogen (BUN) (H), aspartate aminotransferase (AST) (I), and alanine aminotransferase (ALT) (J) levels. Three independent experiments were completed with 3 to 5 mice per group per experiment. Statistically significant differences between individual groups were determined by using the Mann-Whitney test (*, \(P < 0.05\); **, \(P < 0.01\); ***, \(P < 0.001\)).

DENV continues to emerge globally, with an estimated 390 million infections per year (54). Infection by the four distinct serotypes can cause several clinical syndromes, ranging from the debilitating DF to life-threatening shock syndrome. Severe DENV disease most often is associated with a second infection with a heterologous DENV serotype, due to the presence of preexisting and nonneutralizing, cross-reactive antibodies and/or T cells. Although live-attenuated tetravalent prophylactic vaccines are in advanced clinical evaluation (55–58), there is still a need for therapeutics that can be utilized in DENV-infected individuals. Pre-clinical testing has been hampered by the lack of small animal models that support DENV replication and pathogenesis. Most studies have used highly immunocompromised mice lacking intact type I and type II IFN signaling pathways (59). Here, using LysM Cre \(^{+}\) Ifnar\(^{-}\/-\) mice that delete Ifnar expression only on a subset of target myeloid cells, we established a more immunocompetent model of ADE, which shares many of the same clinical features of severe DENV in humans. ADE of DENV-2 or DENV-3 infection in LysM Cre \(^{+}\) Ifnar\(^{-}\/-\) mice resulted in plasma leakage, elevated levels of proinflammatory and vasoactive cytokines in blood, liver injury, hemocoagulation, and thrombocytopenia. We used this more immunocompetent model to establish the therapeutic activity against DENV of a bispecific antibody-based Fc-DART and a RIG-I receptor immunomodulatory agonist.

As a follow-up to these studies, we demonstrated the postexposure therapeutic efficacy of M8 5’-ppp RNA against DENV-2 and DENV-3 infection in LysM Cre \(^{+}\) Ifnar\(^{-}\/-\) mice when the RIG-I agonist was administered 2 days after infection in the setting of ADE (Fig. 7A). Therapeutic administration of M8 5’-ppp RNA after infection with DENV-2 or DENV-3 resulted in improved weight gain in the M8-treated group, with a significant difference in weight at 4 days postinfection compared to the results for the control (Fig. 7B and G). Concurrently, there was a reduction in viremia (Fig. 7C and H), a normalization of platelet levels (Fig. 7D and I), and an improvement in liver function tests (Fig. 7E, F, J, and K) associated with M8 treatment. These results suggest that RIG-I activation is a potential therapeutic target during the course of DENV infection.

DISCUSSION

DENV continues to emerge globally, with an estimated 390 million infections per year (54). Infection by the four distinct serotypes can cause several clinical syndromes, ranging from the debilitating DF to life-threatening shock syndrome. Severe DENV disease most often is associated with a second infection with a heterologous DENV serotype, due to the presence of preexisting and nonneutralizing, cross-reactive antibodies and/or T cells. Although live-attenuated tetravalent prophylactic vaccines are in advanced clinical evaluation (55–58), there is still a need for therapeutics that can be utilized in DENV-infected individuals. Pre-clinical testing has been hampered by the lack of small animal models that support DENV replication and pathogenesis. Most studies have used highly immunocompromised mice lacking intact type I and type II IFN signaling pathways (59). Here, using LysM Cre \(^{+}\) Ifnar\(^{-}\/-\) mice that delete Ifnar expression only on a subset of target myeloid cells, we established a more immunocompetent model of ADE, which shares many of the same clinical features of severe DENV in humans. ADE of DENV-2 or DENV-3 infection in LysM Cre \(^{+}\) Ifnar\(^{-}\/-\) mice resulted in plasma leakage, elevated levels of proinflammatory and vasoactive cytokines in blood, liver injury, hemocoagulation, and thrombocytopenia. We used this more immunocompetent model to establish the therapeutic activity against DENV of a bispecific antibody-based Fc-DART and a RIG-I receptor immunomodulatory agonist.

A prior study showed that LysM Cre \(^{+}\) Ifnar\(^{-}\/-\) mice were vulnerable to DENV-2 infection (40). Rather than try to augment DENV disease using enhancing antibodies as was done in our study, this group showed that an Ifnar deficiency on CD11c\(^{+}\) dendritic cells or LysM\(^{+}\) macrophages resulted in complete lethality...
after infection with a 10-fold-higher dose of DENV-2. The mice lacking Ifnar expression only on myeloid cell subsets developed a robust DENV-specific CD8+ T cell response, compared to a weak response in Ifnar−/− mice, and sustained a protective immune response to a candidate subunit vaccine. Our experiments confirm and extend these findings. First, in the direct DENV-2 infection model in LysM Cre+/Ifnarf/f mice, we observed increased viral infection, elevated levels of cytokines, and altered laboratory parameters without significant mortality, which is characteristic of primary DENV infection in humans. These results confirm that protection of mice from DENV infection depends on type I IFN signaling in LysM-expressing myeloid cells.

A criticism of existing Ifnar-deficient mouse models of DENV is that the type I IFN receptor signaling pathway is required for optimal antigen-specific T and B cell priming, expansion, and memory formation (40). The LysM Cre+ Ifnarfl mice model overcome these limitations and more closely recapitulates several aspects of human disease. The deletion of Ifnar expression on LysM mouse myeloid cells overcomes the species immune antagonism issues and enables higher levels of DENV infection and inflammatory responses in myeloid cells, which are the natural cellular targets in human disease (41). Although LysM Cre+ Ifnarfl mice supported increased DENV replication, showed signs of illness, and developed thrombocytopenia during primary infection, they did not develop hemoconcentration, vascular leakage, or lethality when virus alone was administered. In comparison, when enhancing antibodies against prM and E were provided, the viral burden was greater, and this was associated with more severe disease, including death, as is seen in the most severe cases of dengue in humans.
Another limitation of DENV infection experiments in Ifnar−/− or AG129 mice is that most agonists that modulate innate immune responses cannot be evaluated. There is increasing interest in the development of molecules that can stimulate IRF3 and/or type I IFN responses as means of controlling virus infection. Such agents may be important particularly in the context of DENV, which can inhibit IRF3 and IFN induction by virtue of its ability to antagonize STING-dependent responses (37, 38). However, such agents would not induce robust antiviral responses in mice lacking type I IFN responses in all cells. Indeed, 5′-ppp RNA moieties that activate RIG-I had no therapeutic effect against DENV in Ifnar−/− mice. In comparison, administration of the M8 5′-ppp RNA pathogen-associated molecular pattern protected LysM Cre+ Ifnarf/f mice from severe DENV disease. These experiments establish the utility of the conditional LysM Cre+ Ifnarf/f mouse model for testing possible novel immunomodulatory therapies against DENV.

We previously generated a bispecific tetravalent Ig-DART (E60 and 4E11) and showed protective activity against DENV in AG129 mice (49). In the current study, we used a different cross-reactive DII fusion loop MAb (E119) and a sequence-optimized version of a group-specific MAb (4E11) (52) to create a new bispecific tetravalent Fc-DART with an N297Q modified Fc region that cannot promote ADE in vitro or in vivo. This Fc-DART showed marked protective activity against DENV-2 and DENV-3 in LysM Cre+ Ifnarf/f mice and prevented clinical disease and laboratory parameter abnormalities. These experiments confirm the utility of Fc-modified-antibody-based therapeutics against DENV (24, 26).

In summary, we established LysM Cre+ Ifnarf/f mice as a more immunocompetent model of antibody-enhanced DENV infection in vivo. We demonstrated the utility of this model by administering antibody- or innate immune-based therapeutic agents against two different DENV serotypes, including a non-mouse-adapted DENV-3 strain. Future studies are planned to evaluate the pathogenesis of the remaining two DENV serotypes (DENV-1 and DENV-4) and assess whether disease occurs in LysM Cre+ Ifnarf/f mice using circulating, contemporary, and other non-mouse-adapted isolates.

MATERIALS AND METHODS

Ethics statement. This study was carried out in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocols were approved by the Institutional Animal Care and Use Committee at the Washington University School of Medicine (assurance number A3381-01). Dissections and injections were performed under anesthesia that was induced with ketamine hydrochloride and xylazine.

Viruses and cells. DENV-2 strain D2S20 is a mouse-adapted strain and has been described previously (33). The DENV-3 strain is a non-mouse-adapted isolate.
mouse-adapted DENV-3 Thai human isolate (strain C0360/94) (27). All viruses were passaged in C6/36 Aedes albopictus cells and ultracentrifuged (30,000 RPM for 3 h in a SW32 rotor [110,000 g]) through a 25% glycerol cushion. Pelleted virus was resuspended in 10 mM Tris, pH 8.0, 150 mM NaCl, and 1 mM EDTA, and stored at 80°C. The titers of virus stocks were determined by a focus-forming assay on Vero cells (49).

**Mice.** WT C57BL/6 mice were purchased commercially (Jackson Laboratories). Ifnar−/− mice (61) were backcrossed for 10 generations onto the C57BL/6 background. LysM Cre Ifnar−/− mice were obtained from R. Schreiber (St. Louis, MO) and U. Kalinke (Hannover, Germany). The Ifnar−/− (62) and LysM Cre Ifnar−/− mice were backcrossed using speed congenic analysis to 99% C57BL/6 as judged by microsatellite analysis. Mice (4 to 5 weeks old) were inoculated intravenously with DENV-2 (D2S20) or DENV-3 (C0360/94).

**Analysis of Ifnar expression.** Blood was obtained by intracardiac heart puncture, and spleens were recovered. Live cells were stained with MAb specific for CD11c, CD3, class II major histocompatibility complex (MHC), CD11b, B220, and Ifnar (BioLegend) to define cell types and determine Ifnar expression. All samples were processed on an LSRII or Fortessa flow cytometer (BD Biosciences). The resulting data were analyzed using FlowJo (Treestar).

**Fc-DART generation.** To humanize WNV-E119 antibody (50), the complementarity-determining regions (CDRs) from VH and VL were grafted onto the most homologous human germline antibody framework sequences, VH3-48/VH3-23 and V\_K-30/V\_K-15, respectively. For humanization of the 4E11 antibody (52), the CDRs from VH and VL were grafted onto the human germline antibody framework sequences VH1-46 and V\_K-3, respectively. Necessary framework back mutations were engineered to rescue the antibody binding affinity. The Fc-DART was produced from plasmids that coexpressed two polypeptide chains: chain 1, with the humanized VL domain of WNV-E119 linked to the humanized VH domain of 4E11, followed by a K coil sequence, and chain 2, with the humanized VL of 4E11 linked to the humanized VH of WNV-E119, followed by an E coil sequence and the CH2 and CH3 of the human constant region, containing an N297Q point mutation that abolishes C1q and FcR interactions (63). The oppositely charged E coil and K coil promote the heterodimerization of chain 1 and chain 2, and this assembly is stabilized further by an interchain disulfide bond within the E-coil/K-coil domain. The Fc-DART was expressed in CHO-S cells and purified from supernatants by serial protein A affinity and Superdex 200 size exclusion chromatography to generate purified recombinant material.

**Animal treatments.** (i) ADE studies. To induce ADE, mice were treated via the intravenous route with the flavivirus cross-reactive antibody 4G2 (64) (10 mg/mouse) for DENV-3 or with the combination of dengue complex-specific anti-prM antibody 2H2 (64) and 4G2 (15 mg each MAb per mouse) for DENV-2 one day prior to infection.

(ii) Fc-DART therapy. Mice were treated via an intraperitoneal route with 25 mg/mouse of h4E11–WNV-hE119 N297Q Fc-DART or negative-control recombinant (type-specific DENV-4 hE88 N297Q [13]) IgG either one day prior to infection or at 48 h after infection.

(iii) RIG-I agonist treatment. Mice were treated with a single dose (5 mg/mouse) of a 99-nucleotide, uridine-rich hairpin 5\_ppp RNA termed M8 (53, 65) or a synthetic RNA control lacking 5\_ppp control
combined with jetPEI transfection reagent (Polyplus) via intravenous injection before and after infection.

**qRT-PCR analysis of viral burden.** Fluorogenic quantitative RT-PCR (qRT-PCR) was used to measure viral genome copy number. Total RNA from organs or serum of infected animals was isolated using the Qiagen RNeasy kit or the Qiagen viral RNA isolation kit. DENV viral RNA was determined using the pan-DENV primer probe set (66), which recognizes a conserved sequence in the 3′ untranslated region of all DENV serotypes. Viral copy number was determined using a defined single-stranded RNA generated in vitro using T7 polymerase containing the DENV target sequences.

**Neutralization assay.** Focus-forming reduction neutralization assays (FRNTs) were performed as described previously (49) to determine the 50% inhibitory concentrations of MAbs and Fc-DARTs against the virus isolates used to infect mice. Infected foci were enumerated by counting using a CTL-Immunospot S6 (Cellular Technology Limited).

**Clinical hematology and chemistry analysis.** At specified times after DENV infection of mice, blood was collected by intracardiac heart puncture. Blood for clinical hematology analysis was collected into EDTA-coated tubes (Becton Dickinson), and analyzed using a ProCyte DX machine (IDEXX). Serum was collected for clinical chemistry analysis of alanine transaminase (ALT), aspartate aminotransferase (AST), and blood urea nitrogen (BUN) using the ProCyte DX machine.

**Cytokine and chemokine measurements.** The BioPlex Pro assay (Bio-Rad) was performed according to the manufacturer’s protocol on serum isolated at day 4 postinfection. The cytokine screen included IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12p40, IL-12p70, IL-13, IL-17, Eotaxin, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), IFN-γ, KC, monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1α (MIP-1α), MIP-1β, RANTES (CCL5), and tumor necrosis factor alpha (TNF-α).

**Vascular permeability analysis.** Two hundred microliters of sterile filtered Evans blue solution (0.5% [wt/vol]) in phosphate-buffered saline (PBS) was injected intravenously. After 20 min, mice were sacrificed and perfused with 40 ml of PBS. Livers, spleens, small intestines, and kidneys were collected into tubes containing formamide (Fisher Scientific), homogenized, weighed, and incubated overnight at 25°C. The following day, samples were centrifuged at 14,000 × g and 100 μl of supernatant was quantified at 610 nm against a standard curve generated by serial dilutions of a stock Evans blue solution.

**Statistical analysis.** All data were analyzed using Prism software (GraphPad, San Diego, CA). Kaplan-Meier survival curves were analyzed by the log rank test. Differences in results for viral burden, clinical chemistry and hematology, cytokine levels, and Evans blue staining were analyzed by the Mann-Whitney test.

**ACKNOWLEDGMENTS.** We gratefully acknowledge Ulrich Kalinke and Robert Schreiber for providing the Ifnar−/− and LysMCre+ Ifnar−/− mice and William Tang and William Eddy for technical assistance in some of the experiments.

This work was supported by the Burroughs Wellcome Fund (M.S.D.), NIH grants R01 AI077955 (M.S.D.), R01 AI108661 (J.H.), U54 AI057517 (the Southeastern Regional Center of Excellence for Emerging Infectious and Biodefense), and R56 AI085063 (S.S.). V.V.S. was supported by a T32 postdoctoral fellowship (NIH/IAID AI 7536-13).

**REFERENCES.**


